Artiva Biotherapeutics, Inc. (ARTV) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Artiva Biotherapeutics reported revenue of $0, down 100.0% from $251,000 the year before. Net income was -$83.9M, or -$3.43 per diluted share. Operating activities generated -$76.8M of cash, leaving -$79.4M of free cash flow. At fiscal year end, Artiva Biotherapeutics held $130.9M in total assets against $21.0M in total liabilities, including $26.7M of cash and equivalents.
Open the full interactive Artiva Biotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Artiva Biotherapeutics Key Stats
| Share Price | $6.29 |
|---|---|
| Market Cap | $247.9M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $2.74 – $13.39 |
| Shares Outstanding | 39.4 million (basic, 2026 Q2) |
Artiva Biotherapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $251,000 | $0 |
| Operating Income | -$67.3M | -$89.8M |
| Pre-Tax Income | -$65.4M | -$83.9M |
| Income Tax | $0 | $0 |
| Net Income | -$65.4M | -$83.9M |
| Diluted EPS | -$5.81 | -$3.43 |
Artiva Biotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$21.5M | -$20.8M | -$23.5M | -$25.0M |
| Diluted EPS | -$0.88 | -$0.85 | -$0.95 | -$0.63 |
Artiva Biotherapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $40.2M | $26.7M |
| Current Assets | $188.6M | $112.7M |
| Total Assets | $209.6M | $130.9M |
| Current Liabilities | $12.3M | $13.1M |
| Total Liabilities | $22.9M | $21.0M |
| Shareholders' Equity | $186.6M | $110.0M |
Artiva Biotherapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$55.0M | -$76.8M |
| Cash From Investing | -$120.5M | $63.4M |
| Cash From Financing | $162.2M | $9,000 |
| Free Cash Flow | -$55.6M | -$79.4M |
Figures from Artiva Biotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Artiva Biotherapeutics financials page for every line item.
Artiva Biotherapeutics Company Profile
| Ticker | ARTV |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001817241 |
Frequently Asked Questions
What was Artiva Biotherapeutics' revenue in fiscal 2025?
Artiva Biotherapeutics (ARTV) reported revenue of $0 for fiscal 2025.
What was Artiva Biotherapeutics' net income in fiscal 2025?
Artiva Biotherapeutics reported net income of -$83.9M for fiscal 2025.
What was Artiva Biotherapeutics' earnings per share (EPS) in fiscal 2025?
Artiva Biotherapeutics' diluted EPS was -$3.43 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Artiva Biotherapeutics generate in fiscal 2025?
Artiva Biotherapeutics generated -$79.4M of free cash flow in fiscal 2025.
What was Artiva Biotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Artiva Biotherapeutics reported revenue of $0.
How many shares of Artiva Biotherapeutics are outstanding?
Artiva Biotherapeutics reported a weighted average of 39.4 million basic shares outstanding in 2026 Q2.
What is Artiva Biotherapeutics' market cap?
Based on its latest closing price, Artiva Biotherapeutics (ARTV) has a market capitalization of about $247.9M.
When does Artiva Biotherapeutics' fiscal year end?
Artiva Biotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Artiva Biotherapeutics headquartered?
Artiva Biotherapeutics lists its business address in San Diego, California in its SEC filings.
Artiva Biotherapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →